Clinical trialNCT01208454CompletedPhase 1Interventional

Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

SponsorNational Cancer Institute (NCI)Enrollment29Localized Unresectable NeuroblastomaRecurrent NeuroblastomaRegional NeuroblastomaStage 4 NeuroblastomaStage 4S Neuroblastoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial is studying the side effects and the best dose of vorinostat when given together with isotretinoin to see how well it works in treating patients with high-risk refractory or recurrent neuroblastoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin may help vorinostat work better by making tumor cells more sensitive to the drug. Giving vorinostat together with isotretinoin may be an effective treatment for neuroblastoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Julie Park
New Approaches to Neuroblastoma Treatment (NANT)
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Hospital for Sick Children
Toronto, Ontario, Canada

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
Lucile Packard Children'S Hospital Stanford University
Palo Alto, California, United States
Ucsf Medical Center-Parnassus
San Francisco, California, United States
Children'S Hospital Colorado
Aurora, Colorado, United States
Children'S Healthcare of Atlanta - Egleston
Atlanta, Georgia, United States
University of Chicago Comer Children'S Hospital
Chicago, Illinois, United States
Boston Children'S Hospital
Boston, Massachusetts, United States
C S Mott Children'S Hospital
Ann Arbor, Michigan, United States
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Cook Children'S Medical Center
Fort Worth, Texas, United States
Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Isotretinoin →Vorinostat →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2010
Primary completion: 30 Sept 2014
Completion: —
Last update posted: 24 Nov 2015
Registered enrollment: 29
Registry id: NCT01208454

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.